Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analytical approach

被引：0
|
作者：
Grossi, Francesco
Belvedere, Ornella
Defferrari, Carlotta
Rosetti, Francesco
Vinante, Orazio
Pappagallo, Giovanni
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Udine, I-33100 Udine, Italy
[3] Osped PF Calvi, Noale, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [21] Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma
    Vallejo, C
    Romero, A
    Perez, J
    Cuevas, M
    Lacava, J
    Sabatini, C
    Dominguez, M
    Rodriguez, R
    Barbieri, M
    Acuna, LR
    Acuna, JR
    Langhi, M
    Amato, S
    Salvadori, M
    Ortiz, E
    Machiavelli, M
    Leone, B
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (06): : 584 - 588
  • [22] Correlates of benefit from induction chemotherapy before radiotherapy in non-small cell lung cancer (NSCLC): A meta-analytical approach with meta-regression analysis
    Bozcuk, H. S.
    Ozdogan, M.
    Artac, M.
    Yildiz, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [24] Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    da Silveira Nogueira Lima, Joao Paulo
    dos Santos, Lucas Vieira
    Sasse, Emma Chen
    Sasse, Andre Deeke
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 601 - 607
  • [25] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [26] Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis
    Berghmans, Thierry
    Paesmans, Marianne
    Meert, Anne-Pascale
    Tiseo, Marcello
    Sculier, Jean-Paul
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [27] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [29] ACTIVITY AND TOLERABILITY OF CARBOPLATIN AND GEMCITABINE IN FIRST-LINE TREATMENT OF ELDERLY THAI PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Charoentum, Chaiyut
    Theerakittikul, Theerakorn
    Saeteng, Somcharone
    Euathrongchit, Juntima
    Lertprasertsuke, Nirush
    Ariyawutyakorn, Witthawat
    Chewaskulyong, Busyamas
    Thongprasert, Sumitra
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1313 - S1313
  • [30] Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC)
    Lewis, Jacob
    Woodhouse, Laura
    Adderley, Helen
    Carter, Matt
    Brown, Kate
    Morrissey, George
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin
    LUNG CANCER, 2023, 178 : S34 - S34
12345